Development and Evaluation of a Pilot Nurse Case Management Model to Address Multidrug-Resistant Tuberculosis (MDR-TB) and HIV in South Africa

被引:19
|
作者
Farley, Jason E. [1 ]
Kelly, Ana M. [2 ]
Reiser, Katrina [1 ]
Brown, Maria [1 ]
Kub, Joan [1 ,3 ]
Davis, Jeane G. [1 ]
Walshe, Louise [3 ]
Van der Walt, Martie [4 ]
机构
[1] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21205 USA
[2] Michigan State Univ, Coll Nursing, E Lansing, MI 48824 USA
[3] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[4] MRC, TB Epidemiol & Intervent Res Unit, Pretoria, South Africa
来源
PLOS ONE | 2014年 / 9卷 / 11期
基金
美国国家卫生研究院;
关键词
XDR-TB; GUIDELINES; INFECTION; EPIDEMIC; CARE;
D O I
10.1371/journal.pone.0111702
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Setting: Multidrug-resistant tuberculosis (MDR-TB) unit in KwaZulu-Natal, South Africa. Objective: To develop and evaluate a nurse case management model and intervention using the tenets of the Chronic Care Model to manage treatment for MDR-TB patients with a high prevalence of human immunodeficiency virus (HIV) co-infection. Design: A quasi-experimental pilot programme utilizing a nurse case manager to manage care for 40 hospitalized MDR-TB patients, 70% HIV co-infected, during the intensive phase of MDR-TB treatment. Patients were followed for six months to compare proximal outcomes identified in the model between the pre- and post-intervention period. Results: The greatest percent differences between baseline and six-month MDR-TB proximal outcomes were seen in the following three areas: baseline symptom evaluation on treatment initiation (95% improvement), baseline and monthly laboratory evaluations completed per guidelines (75% improvement), and adverse drug reactions acted upon by medical and/or nursing intervention (75% improvement). Conclusion: Improvements were identified in guideline-based treatment and monitoring of adverse drug reactions following implementation of the nurse case management intervention. Further study is required to determine if the intervention introduced in this model will ultimately result in improvements in final MDR-TB treatment outcomes.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] A prioritised research agenda for DOTS-Plus for multidrug-resistant tuberculosis (MDR-TB)
    Gupta, R
    Espinal, M
    Beggs, A
    Laing, R
    Preger, J
    Castro, K
    Cegielski, JP
    De Luca, N
    Laserson, K
    Walton, W
    Wells, C
    Erokhin, V
    Mishin, V
    Vassilieva, I
    Karataev, ON
    Drobniewski, F
    Brander, L
    Katila, ML
    Malakhov, I
    Safonova, S
    Sheyanenko, O
    Starchenkova, N
    Farmer, P
    Hiatt, H
    Kim, J
    Mukherjee, J
    Murray, M
    Becerra, M
    Nardell, E
    Palmero, DJ
    Bonilla, C
    Solovic, I
    Mahmud, AM
    Rahman, A
    Melnyk, VM
    Portaels, F
    Creach, P
    Billo, N
    Repina, E
    Rakhishev, G
    Pechiorina, I
    Squire, SB
    Coker, R
    Arora, VK
    Sloutsky, A
    Timperi, R
    Henkens, M
    Lafontaine, D
    Slavuckij, A
    Vezhnina, N
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2003, 7 (05) : 410 - 414
  • [32] Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)
    Liu, Yongge
    Matsumoto, Makoto
    Ishida, Hidekaza
    Ohguro, Kinue
    Yoshitake, Masuhiro
    Gupta, Rajesh
    Geiter, Lawrence
    Hafkin, Jeffrey
    TUBERCULOSIS, 2018, 111 : 20 - 30
  • [33] Management of multidrug resistant tuberculosis (MDR-TB) - Monitoring is the key to successful outcome
    Akshata, J. S.
    Chakrabarthy, Anushree
    EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2016, 65 (02): : 447 - 450
  • [34] Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications
    Ali, Monadil H.
    Alrasheedy, Alian A.
    Kibuule, Dan
    Godman, Brian
    Hassali, Mohamed Azmi
    Ali, Hamdan Mustafa Hamdan
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2019, 17 (11) : 927 - 937
  • [35] Multidrug-resistant tuberculosis (MDR-TB) in a black African carceral area: Experience of Mali
    Toloba, Y.
    Ouattara, K.
    Soumare, D.
    Kanoute, T.
    Berthe, G.
    Baya, B.
    Konate, B.
    Keita, M.
    Diarra, B.
    Cisse, A.
    Camara, F. S.
    Diallo, S.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2018, 74 (01) : 22 - 27
  • [36] Prevalence and Factors Associated with Multidrug-Resistant Tuberculosis (MDR-TB) among Presumptive MDR-TB Patients in Tigray Region, Northern Ethiopia
    Mehari, Kibriti
    Asmelash, Tsehaye
    Hailekiros, Haftamu
    Wubayehu, Tewolde
    Godefay, Hagos
    Araya, Tadele
    Saravanan, Muthupandian
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2019, 2019
  • [37] Increase in Multidrug-resistant Tuberculosis (MDR-TB) in Alberta Among Foreign-born Persons: Implications for Tuberculosis Management
    Richard Long
    Deanne Langlois-Klassen
    Canadian Journal of Public Health, 2013, 104 : e22 - e27
  • [38] Increase in Multidrug-resistant Tuberculosis (MDR-TB) in Alberta Among Foreign-born Persons: Implications for Tuberculosis Management
    Long, Richard
    Langlois-Klassen, Deanne
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2013, 104 (01): : E22 - E27
  • [39] Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
    Coker, R
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2002, 6 (08) : 649 - 650
  • [40] Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
    Gupta, R
    Raviglione, MC
    Espinal, MA
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2001, 5 (12) : 1078 - 1079